Orthofix Medical Inc.
NASDAQ:OFIXMedical - Devices
+$0.03 today
- Market cap
- $269.42M
- Beta
- 0.71
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.48
Volume 0.40M
Average 0.38M
OFIX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Orthofix Medical Inc.NASDAQ: OFIX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $15.32M fell 22.5% year over year, behind the -16.9% change in trailing-twelve-month research & development. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.
Context
- Research & development amounted to 6.9% of revenue in FY2025, down 2.3 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -22.5% toward the trailing-twelve-month pace of -16.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 57.11M USD
- Year-over-year change
- -22.4%
- 4-year CAGR
- +3.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.11M | -22.4% |
| FY2024 | 2024-12-31 | 73.64M | -8.2% |
| FY2023 | 2023-12-31 | 80.23M | +63.5% |
| FY2022 | 2022-12-31 | 49.07M | -1.1% |
| FY2021 | 2021-12-31 | 49.62M | — |
Research & Development vs competitors
How OFIX compares with its peers on the latest reported figures
- OFIX's LTM Mar 2026 research & development of $61.4M is the 5th highest of the 11 companies compared; the peer median is $40.08M.
- Its year-over-year change of -16.9% is the 8th highest of 11, against a peer median of -2.7%.
- Research & development amounts to 7.4% of revenue for OFIX, versus a peer median of 26.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Apr 2026 | $89.5M | +0.1% | +5.8% | 10.4% | |
| LTM Mar 2026 | $87.86M | -27.1% | -20.4% | 54.9% | |
| LTM Mar 2026 | $84.33M | +24.0% | +11.4% | 4593.1% | |
| LTM Mar 2026 | $61.4M | -16.9% | +5.2% | 7.4% | |
| LTM Mar 2026 | $44.28M | -2.4% | -26.2% | 10.6% | |
| LTM Mar 2026 | $35.88M | -3.0% | -25.6% | 34.9% | |
| LTM Mar 2026 | $22.9M | -6.9% | -8.9% | 3.2% | |
| LTM Mar 2026 | $22.48M | -43.6% | -11.4% | 26.1% | |
| LTM Mar 2026 | $17.11M | +2.1% | +8.6% | 8.3% | |
| LTM Mar 2026 | $12.07M | -44.2% | -11.1% | 56.9% | |
| Peer median (excluding OFIX) | $40.08M | -2.7% | -10.0% | 26.1% | |
Competitors are the stored peer set for OFIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 464.48M | 460.71M | 746.64M | 799.49M | 822.31M |
| Cost of Revenue | 114.91M | 123.54M | 260.37M | 253.61M | 270.61M |
| Gross Profit | 349.57M | 337.17M | 486.27M | 545.89M | 551.71M |
| Gross Margin | 75.3% | 73.2% | 65.1% | 68.3% | 67.1% |
| Research & Development | 49.62M | 49.07M | 80.23M | 73.64M | 57.11M |
| Selling, General & Admin | 290.67M | 308.78M | 530.4M | 532.53M | 456.39M |
| Operating Expenses | 357.88M | 350.44M | 625.38M | 630.5M | 620.18M |
| Depreciation & Amortization | 33.1M | 32.08M | 60.56M | 60.06M | 50.97M |
| EBITDA | 21.44M | 15.66M | (79.49M) | (34.18M) | (22.35M) |
| EBITDA Margin | 4.6% | 3.4% | -10.6% | -4.3% | -2.7% |
| Operating Income | (8.32M) | (13.27M) | (139.11M) | (84.62M) | (68.47M) |
| Operating Margin | -1.8% | -2.9% | -18.6% | -10.6% | -8.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.84M | 1.29M | 8.63M | 29.63M | 17.49M |
| Other Income / Expenses | (5.18M) | (4.44M) | (9.57M) | (39.26M) | (22.34M) |
| Income Before Tax | (13.5M) | (17.71M) | (148.68M) | (123.88M) | (90.81M) |
| Pre-Tax Margin | -2.9% | -3.8% | -19.9% | -15.5% | -11.0% |
| Income Tax Expense | 24.88M | 2.04M | 2.72M | 2.12M | 1.38M |
| Net Income | (38.38M) | (19.75M) | (151.4M) | (126M) | (92.19M) |
| Net Margin | -8.3% | -4.3% | -20.3% | -15.8% | -11.2% |
| EPS (Basic) | (1.95) | (0.98) | (4.12) | (3.30) | (2.28) |
| EPS (Diluted) | (1.95) | (0.98) | (4.12) | (3.30) | (2.28) |
| Weighted Avg Shares | 19.69M | 20.1M | 36.73M | 38.13M | 39.88M |
| Weighted Avg Shares (Diluted) | 19.69M | 20.1M | 36.73M | 38.13M | 39.88M |
Orthofix Medical Inc.
NASDAQ:OFIX
Intrinsic Alpha fair value
Locked
Current Price
$6.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.